Alpha 2.0
Login Register
» Articles » PMID: 24029743

Design of the Subpopulations and Intermediate Outcomes in COPD Study (SPIROMICS)

Overview
Journal Thorax
Date 2013 Sep 14
PMID 24029743
Citations 244
Authors
David Couper
Lisa M LaVange
MeiLan Han
R Graham Barr
Eugene Bleecker
Eric A Hoffman
Richard Kanner
Eric Kleerup
Fernando J Martinez
Prescott G Woodruff
Stephen Rennard
Affiliations
Soon will be listed here.
Abstract

Subpopulations and Intermediate Outcomes in COPD Study (SPIROMICS) is a multicentre observational study of chronic obstructive pulmonary disease (COPD) designed to guide future development of therapies for COPD by providing robust criteria for subclassifying COPD participants into groups most likely to benefit from a given therapy during a clinical trial, and identifying biomarkers/phenotypes that can be used as intermediate outcomes to reliably predict clinical benefit during therapeutic trials. The goal is to enrol 3200 participants in four strata. Participants undergo a baseline visit and three annual follow-up examinations, with quarterly telephone calls. Adjudication of exacerbations and mortality will be undertaken.

Citing Articles

Quantitative CT and COPD: cluster analysis reveals five distinct subtypes with varying exacerbation risks.

Peng C, Chen Z, Zhou H, Dai C, Yuan H, Gao Y BMC Pulm Med. 2025; 25(1):92.

PMID: 40011880 PMC: 11863429. DOI: 10.1186/s12890-025-03562-8.

Classifying COVID-19 hospitalizations in epidemiology cohort studies: The C4R study.

Oelsner E, Krishnaswamy A, Rustamov R, Balte P, Ali T, Allen N PLoS One. 2025; 20(2):e0316198.

PMID: 39928595 PMC: 11809881. DOI: 10.1371/journal.pone.0316198.

Novel risk loci encompassing genes influencing STAT3, GPCR, and oxidative stress signaling are associated with co-morbid GERD and COPD.

Wilson A, Rocco A, Chiles J, Srinivasasainagendra V, Labaki W, Meyers D PLoS Genet. 2025; 21(2):e1011531.

PMID: 39919125 PMC: 11805425. DOI: 10.1371/journal.pgen.1011531.

MRI-assessed Dynamic Hyperinflation Induced by Tachypnea in Chronic Obstructive Pulmonary Disease: The SPIROMICS-HF Study.

Zhang X, Cooper C, Prince M, Ambale-Venkatesh B, Agarwal P, Backman M Radiol Cardiothorac Imaging. 2025; 7(1):e240053.

PMID: 39836055 PMC: 11880862. DOI: 10.1148/ryct.240053.

Metabolic Aging as an Increased Risk for Chronic Obstructive Pulmonary Disease.

Guo C, Godbole S, Labaki W, Pratte K, Curtis J, Paine R Metabolites. 2024; 14(12).

PMID: 39728428 PMC: 11677693. DOI: 10.3390/metabo14120647.

References
1.
Vestbo J, Anderson W, Coxson H, Crim C, Dawber F, Edwards L . Evaluation of COPD Longitudinally to Identify Predictive Surrogate End-points (ECLIPSE). Eur Respir J. 2008; 31(4):869-73. DOI: 10.1183/09031936.00111707. View
2.
Regan E, Hokanson J, Murphy J, Make B, Lynch D, Beaty T . Genetic epidemiology of COPD (COPDGene) study design. COPD. 2010; 7(1):32-43. PMC: 2924193. DOI: 10.3109/15412550903499522. View
3.
Vestbo J, Rennard S . Chronic obstructive pulmonary disease biomarker(s) for disease activity needed--urgently. Am J Respir Crit Care Med. 2010; 182(7):863-4. DOI: 10.1164/rccm.201004-0602ED. View
4.
Minino A, Xu J, Kochanek K . Deaths: preliminary data for 2008. Natl Vital Stat Rep. 2014; 59(2):1-52. View